Relating genotype and phenotype in breast cancer: An analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations

Cancer Research

Volumn 60, Issue 4, 2000, Pages 1077-1083

  Cuny, Marguerite ^c   Kramar, Andrew ^c   Courjal, Frank ^c   Johannsdottir, Vala ^c   Iacopetta, Barry ^a   Fontaine, Hélène ^c   Grenier, Jean ^c   Culine, Stéphane ^c   Theillet, Charles ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN P53;

ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CHROMOSOME MAP; CONTROLLED STUDY; GENE AMPLIFICATION; GENE LOCUS; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CHROMOSOME MAPPING; CYCLIN D1; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; GENES, MYC; GENES, P53; GENOTYPE; HUMANS; MULTIVARIATE ANALYSIS; MUTATION; NUCLEAR PROTEINS; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 0034652452     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology [see comments]. J. Clin. Oncol., 14: 2843-2877, 1996.
2. Lengauer, C., Kinzler, K. W., and Vogelstein, B. Genetic instabilities in human cancers. Nature (Lond.), 396: 643-649, 1998.
3. Theillet, C. Full speed ahead for tumor screening. Nat. Med., 4: 767-768, 1998.
4. Courjal, F., Cuny, M., Simony-Lafontaine, J., Louason, G., Speiser, P., Zeillinger, R., Rodriguez, C., and Theillet, C. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res., 57: 4360-4367, 1997.
5. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
6. Peto, R., Pike, M. C. Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., and Smith, P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer, 35: 1-39, 1977.
7. Cox, D. R., and McCullagh, P. Some aspects of analysis of covariance. Biometrics, 38: 541-561, 1982.
8. Bautista, S., Valles, H., Walker, R. L., Anzick, S., Zeillinger, R., Meltzer, P., and Theillet, C. In breast cancer, amplification of the steroid receptor coactivator gene A1B1 is correlated with estrogen and progesterone receptor positivity. Clin. Cancer Res., 4: 2925-2929, 1998.
9. Blanckaert, V. D., Hebbar, M., Louchez, M. M., Vilain, M. O., Schelling, M. E., and Peyrat, J. P. Basic fibroblast growth factor receptors and their prognostic value in human breast cancer. Clin. Cancer Res., 4: 2939-2947, 1998.
10. Jiang, M., Shao, Z. M., Wu, J., Lu, J. S., Yu, L. M., Yuan, J. D., Han, Q. X., Shen, Z. Z., and Fontana, J. A. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int. J. Cancer, 74: 529-534, 1997.
11. Piette, J., Neel, H., and Marechal, V. Mdm2: keeping p53 under control. Oncogene, 15: 1001-1010, 1997.
12. Andersen, T. I., Holm, R., Nesland, J. M., Heimdal, K. R., Ottestad, L., and Borresen, A. L. Prognostic significance of TP53 alterations in breast carcinoma. Br. J. Cancer, 68: 540-548, 1993.
13. Bergh, J., Norberg, T., Sjögren, S., Lindgren, A., and Holmberg, L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med., 1: 1029-1034, 1995.
14. Gretarsdottir, S., Tryggvadottir, L., Jonasson, J. G., Sigurdsson, H., Olafsdottir, K., Agnarsson, B. A., Ogmundsdottir, H., and Eyfjord, J. E. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br. J. Cancer, 74: 555-561, 1996.
15. Kovach, J. S., Hartmann, A., Blaszyk, H., Cunningham, J., Schaid, D., and Sommer, S. S. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc. Natl. Acad. Sci. USA, 93: 1093-1096, 1996.
16. Seshadri, R., Leong, A. S., McCaul, K., Firgaira, F. A., Setlur, V., and Horsfall, D. J. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis [published erratum in Int. J. Cancer, 69: 354, 1996]. Int. J. Cancer, 69: 135-141, 1996.
17. Soong, R., Iacopetta, B. J., Harvey, J. M., Sterrett, G. F., Dawkins, H. J., Hahnel, R., and Robbins, P. D. Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Int. J. Cancer, 74: 642-647, 1997.
18. Berns, E. M., van Staveren, I. L., Look, M. P., Smid, M., Klijn, J. G., and Foekens, J. A. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br. J. Cancer, 77: 1130-1136, 1998.
19. Elledge, R. M., Fuqua, S. A. W., Clark, G. M., Pujol, P., Allred, D. C., and McGuire, W. L. Prognostic significance of p53 alterations in node-negative breast cancer. Breast Cancer Res. Treat., 26: 225-235, 1993.
20. Falette, N., Paperin, M. P., Treilleux, I., Gratadour, A. C., Peloux, N., Mignotte, H., Tooke, N., Lofman, E., Inganas, M., Bremond, A., Ozturk, M., and Puisieux, A. Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res., 58: 1451-1455, 1998.
21. Iacopetta, B., Grieu, F., Powell, B., Soong, R., McCaul, K., and Seshadri, R. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Clin. Cancer Res., 4: 1597-1602, 1998.
22. Hainaut, P., Soussi, T., Shomer, B., Hollstein, M., Greenblatt, M., Hovig, E., Harris, C. C., and Montesano, R. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res., 25: 151-157, 1997.
23. Borresen, A. L., Andersen, T. I., Eyfjord, J. E., Cornelis, R. S., Thorlacius, S., Borg, A., Johansson, U., Theillet, C., Scherneck, S., and Hartman, S. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer, 14: 71-75, 1995.
24. Tanner, M. M., Tirkkonen, M., Kallioniemi, A. H., Holli, K., Collins, C., Kowbel, D., Gray, J. W., Kallioniemi, O. P., and Isola, J. Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin. Cancer Res., 1: 1455-1461, 1995.
25. Collins, C., Rommens, J. M., Kowbel, D., Godfrey, T., Tanner, M., Hwang, S. I., Polikoff, D., Nonet, G., Cochran, J., Myambo, K., Jay, K. E., Froula, J., Cloutier, T., Kuo, W. L., Yaswen, P., Dairkee, S., Giovanola, J., Hutchinson, G. B., Isola, J., Kallioniemi, O. P., Palazzolo, M., Martin, C., Ericsson, C. Pinkel, D., Albertson, D., Li, W. B., and Gray, J. W. Positional cloning of ZNF217 and NAKC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc. Natl. Acad. Sci. USA, 95: 8703-8708, 1998.
26. Zhou, H., Kuang, J., Zhong, L., Kuo, W. L., Gray, J. W., Sahin, A., Brinkley, B. R., and Sen. S. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat. Genet., 20: 189-193, 1998.
27. Revillion, F., Bonneterre, J., and Peyrat, J. P. ERBB2 oncogene in human breast cancer and its clinical significance. Eur. J. Cancer, 34: 791-808, 1998.
28. Schuuring, E., Verhoeven, E., Van Tinteren, H., Peterse, J. L., Nunnink, B., Thunnissen, F. B. J. M., Devilee, P., Cornelisse, C. J., van de Vijver, M. J., Mooi, W. J., and Michalides, R. J. A. M. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res., 52: 5229-5234, 1992.
29. Henry, J. A., Hennessy, C., Levett, D. L., Lennard, T. W., Westley, B. R., and May, F. E. int-2 amplification in breast cancer: association with decreased survival and relationship to amplification of c-erbB-2 and c-myc. Int. J. Cancer, 53: 774-780, 1993.
30. Champeme, M. H., Bieche, I., Hacene, K., and Lidereau, R. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer. Mod. Pathol., 7: 900-905, 1994.
31. Hui, R., Campbell, D. H., Lee, C. S., McCaul, K., Horsfall, D. J., Musgrove, E. A., Daly, R. J., Seshadri, R., and Sutherland, R. L. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene, 15: 1617-1623, 1997.
32. Brookes, S., Lammie, G. A., Schuuring, E., de Boer, C., Michalides, R., Dickson, C., and Peters, G. Amplified region of chromosome band 11q13 in breast and squamous cell carcinomas encompasses three CpG islands telomeric of FGF3, including the expressed gene EMS1. Genes Chromosomes Cancer, 6: 222-231, 1993.
33. Bautista, S., and Theillet, C. CCND1 and FGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei. Genes Chromosomes Cancer, 22: 268-277, 1998.
34. Nowell, P. C. Mechanism of tumor progression. Cancer Res., 46: 2203-2207, 1986.
35. Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., and Kallioniemi, O. P. Tissue microarrays for high-throughout molecular profiling of tumor specimens [see comments]. Nat. Med., 4: 844-847, 1998.